March 30 (Reuters) - The United Kingdom should agree to regular increases in NHS drug prices and phase out a multibillion-pound rebate scheme if Eli Lilly LLY.N is to resume investment in the country, Patrik Jonsson, president of Lilly's international businesses told FT on Monday.
Jonsson told FT that he was in talks with ministers in the UK and feeling "optimistic" about reaching an agreement by the summer for Britain to pay more for its medicines.